• Special Issue Topic

    The Future of Biomarkers in CNS Diseases

    Submission Deadline: September 01, 2022

    Guest Editor

    Dr. Vijay K Sharma E-Mail

    Associate Professor, Yong Loo Lin School of Medicine, National University of Singapore; Senior Consultant, Division of Neurology, Department of Medicine, National University Health System, Singapore

    Research Keywords: acute stroke; cerebral hemodynamics; intracranial stenosis; transcranial Doppler; carotid stenosis; thrombolysis

    About the Special Issue

    Neurological disorders are among the leading causes of mortality and long-term disability. Prolonged survival and aging population are increasing the social and economic burden despite considerable improvements in medical care. The ever-increasing pressure on health-care systems led to the development of better methods for early identification and treatment of diseases, in addition to early prognostication. As a result, novel methods for rapid diagnosis and treatment have evolved during last 2 decades. Importantly, development of biological markers has improved the diagnostic accuracy and risk stratification, in addition to monitoring the disease process. However, only a few of them have been integrated into clinical practice.

    This special edition of Explorations of Neuroprotective Therapy aims at providing an overview of the biomarkers for various neurological disorders. Authors describe currently available biomarkers as well as those in various stages of development, which may help in a better understanding of the disease process and improving healthcare delivery as well as outcomes in various neurological disorders.

    Call for Papers

    Published Articles

    Open Access
    Biomarkers in neurodegenerative diseases: a broad overview
    Degeneration and dysfunction of neurons in the brain are hallmarks of neurodegenerative diseases. Over the past decades, significant efforts have been devoted to the development and validation of bi [...] Read more.
    Sathish Selvam, Velpandi Ayyavoo
    Published: April 16, 2024 Explor Neuroprot Ther. 2024;4:119–147
    DOI: https://doi.org/10.37349/ent.2024.00075
    Times Cited: 0
    Open Access
    The diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in children
    Over the last two decades, immunoglobulin G (IgG) antibodies against myelin oligodendrocyte glycoprotein (MOG), previously thought to be a biomarker of multiple sclerosis (MS), have been shown to ca [...] Read more.
    Ünsal Yılmaz
    Published: February 27, 2024 Explor Neuroprot Ther. 2024;4:38–54
    DOI: https://doi.org/10.37349/ent.2024.00069
    Times Cited: 0
    Open Access
    Neuroprotective agents in acute ischemic stroke
    Acute ischemic stroke (AIS) is the leading cause of disability and one of the top causes of mortality worldwide. The current standard of care is reperfusion therapy including intravenous thrombolysi [...] Read more.
    Grace YY Chia ... Benjamin YQ Tan
    Published: February 28, 2023 Explor Neuroprot Ther. 2023;3:47–70
    DOI: https://doi.org/10.37349/ent.2023.00037
    Open Access
    Biomarkers in small fiber neuropathy
    Small fiber neuropathy (SFN) is a relatively common, but largely understudied neurological syndrome which has affected the lives of many globally. The common symptoms of SFN include pain, dysesthesi [...] Read more.
    Amanda C. Y. Chan ... Joy Vijayan
    Published: December 30, 2022 Explor Neuroprot Ther. 2022;2:264–283
    DOI: https://doi.org/10.37349/ent.2022.00033
    Times Cited: 0
    Open Access
    Overview of biomarkers in myasthenia gravis
    Myasthenia gravis (MG) is a rare auto-immune neuromuscular junction (NMJ) disorder which is caused by formation of autoantibodies and destruction of NMJ components. The MG diagnosis is based on the  [...] Read more.
    Fatemeh Afrashteh, Rayan Rajabi
    Published: October 31, 2022 Explor Neuroprot Ther. 2022;2:210–225
    DOI: https://doi.org/10.37349/ent.2022.00029
    Times Cited: 0